Table 1.
Clinical characteristics of study participants.
| ANA- oligo JIA | ANA+ oligo JIA | |
|---|---|---|
| Sex | 11 Female, 2 Male | 14 Female, 1 Male |
| Age (years) at onset | 5.1 ± 2.4 (2 – 11) | 5.1 ± 3.2 (2 – 13) |
| <6 years at onset | 8 subjects | 10 subjects |
| Active joints at onset | 1.3 ± 0.6 (1 – 3) | 1.7 ± 1.0 (1 – 4) |
| Age (years) at first sampling | 8.6 ± 3.1 (4 – 14.5) | 9.1 ± 5.8 (2.5 – 20) |
| Active joints at first sampling | 1.5 ± 0.7 (1 – 3) | 1.9 ± 0.9 (1 – 4) |
| New onset at first sampling | 5 subjects | 5 subjects |
| Disease course | 11 persistent, 2 extended, 1 unknown | 12 persistent, 2 extended, 1 undifferentiated |
| Medication at first sampling | 1 ADA, 1 LEF, 2 MTX | 1 ADA, 1 ETA, 3 MTX |
Summary values are mean ± standard deviation, with the range indicated in brackets. One patient from each ANA group provided samples at 2 distinct arthritic flares. See Table S1 for additional information. Oligo, oligoarticular; JIA, juvenile idiopathic arthritis; ANA, antinuclear antibody; ADA, adalimumab; ETA, etanercept; LEF, leflunomide; MTX, methotrexate.